VIENNA, Austria, June 23, 2010 /PRNewswire/ -- EUCODIS Bioscience, a developer and manufacturer of customized enzymes today announced that it has launched a high-performance beta-lactamase designed to inactivate a broad range of beta-lactam antibiotics. EUCODIS Bioscience is marketing the product under the LacBuster(TM) brand.
Beta-lactamases are enzymes that inactivate beta-lactam antibiotics, hydrolyzing the beta-lactam ring, a molecular structure common to these drugs. This property makes beta lactamases an important tool in the manufacture of beta-lactam antibiotics, where they are used for sterility testing of bulk products. Within the USD 25 billion antibiotics market, beta-lactam antibiotics are the most widely prescribed group of drugs. Beta-lactamase enzymes are also used by the diagnostics industry, and in other areas.
"Our LacBuster(TM) beta-lactamase addresses the needs of leading antibiotics manufacturers, as it inactivates all relevant beta-lactam antibiotics, including penicillins, cephalosporins up to the 5th generation, and carbapenems, and shows an activity significantly higher than that of other products currently in the market", said Bhupinder Hundle, Senior Vice President Marketing & Sales, EUCODIS Bioscience.
"The launch of a product that provides a better performance than previously available in the market demonstrates that we are deeply committed to helping pharmaceutical manufacturers and drug developers keeping their competitive edge", said Thomas Fischer, CEO EUCODIS Bioscience. "At the same time, demand from the broader chemical industry is gaining momentum. With our enzyme products as well as our custom-engineering and manufacturing services we have been making strong inroads in areas such as specialty chemicals, cosmetics, animal feeds, as well as high-value products from biomass."
About EUCODIS Bioscience
EUCODIS Bioscience provides enzymes to the chemical, health care, and other industries, and offers custom-engineering and custom-manufacturing services.
Customers use EUCODIS Bioscience' enzymes and services to make their manufacturing processes more efficient and cleaner and to introduce products with superior properties. The Company's technology of in vivo-recombination is a proven tool for the directed evolution of enzymes that perform to customers' specific requirements.
Enzymes are proteins that catalyze highly specific chemical reactions, offering a safer, cleaner, and competitive alternative to traditional chemistry. They are at the center of industrial, or "white" biotechnology, a fast growing industry segment with sales in excess of EUR100 billion.
Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with a subsidiary in Germany.
For more information, please visit http://www.eucodisbioscience.com Company contact EUCODIS Bioscience: Thomas Fischer CEO EUCODIS Bioscience Campus Vienna Biocenter II Viehmarktgasse 2 a/ 2 OG A-1030 Vienna AUSTRIA +43-1-8900804 firstname.lastname@example.org Media contact EUCODIS Bioscience: Frank Butschbacher Investor Relations & Communications http://www.butschbacher.net +43-650-7844940 email@example.com
SOURCE EUCODIS Bioscience